Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration

NCT04522167 is registered in ClinicalTrials.gov with Bioeq GmbH as lead sponsor.

NCT NCT04522167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04522167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
Lead sponsor
Bioeq GmbH
Phase
Phase 3
Overall status
Completed
Start date
July 21, 2020
Completion date
May 18, 2023
Enrollment
434 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration